Upcoming Conference Calls, Halt in Product Line Distribution, and Approval of Application - Analyst Notes on Intuitive Surgical, Stryker, Smith & Nephew, Varian Medical Systems and Align Technology

Thu Jun 26, 2014 6:00am EDT

* Reuters is not responsible for the content in this press release.

Upcoming Conference Calls, Halt in Product Line Distribution, and Approval of Application - Analyst Notes on Intuitive Surgical, Stryker, Smith & Nephew, Varian Medical Systems and Align Technology

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, June 26, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Intuitive Surgical, Inc. (NASDAQ: ISRG), Stryker Corporation (NYSE: SYK), Smith & Nephew plc (NYSE: SNN), Varian Medical Systems, Inc. (NYSE: VAR) and Align Technology, Inc. (NASDAQ: ALGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4132-100free.

Intuitive Surgical, Inc. Analyst Notes
On June 16, 2014, Intuitive Surgical, Inc. (Intuitive Surgical) announced that it will host a conference call to discuss the Q2 2014 financial results on July 22, 2014 at 4:30 p.m. ET. The call will be webcast by NASDAQ OMX and can be accessed at Intuitive Surgical's Investor Relations site. The full analyst notes on Intuitive Surgical are available to download free of charge at:


Stryker Corporation Analyst Notes
On June 12, 2014, Stryker Corporation (Stryker) announced that it will host a conference call to discuss the Company's operating results of Q2 2014, as well as provide an operational update on July 17, 2014 at 4:30 p.m. ET. A copy of the operating results will be released prior to the call at 4:00 p.m. ET. The webcast of the call, as well as its replay, will be accessible via the Company's Investor Relations site, wherein an archived version will also be available for 90 days. The full analyst notes on Stryker are available to download free of charge at:


Smith & Nephew plc Analyst Notes
On June 23, 2014, Smith & Nephew plc (Smith & Nephew) announced that it has temporarily ceased commercial distribution of its RENASYS Negative Pressure Wound Therapy (NPWT) product line in the US, following instruction from the Food and Drug Authority (FDA) to obtain new regulatory clearances in respect of certain design enhancements made to RENASYS systems. The Company informed that the commercial distribution only affects RENASYS products in the US while other NPWT products such as PICO, Smith & Nephew's portable, canister-free system are unaffected. At present, the Company is working with FDA to address the concerns in order to resume distribution in the US, as the applications for clearance have been filed and are awaiting action. The full analyst notes on Smith & Nephew are available to download free of charge at:


Varian Medical Systems, Inc. Analyst Notes
On June 23, 2014, Varian Medical Systems, Inc. (Varian Medical Systems) announced that it will release its Q3 FY 2014 financial results on July 23, 2014, after the market close. A news release will be issued, followed by a teleconference call at 2:00 p.m. PT on the same day. The release and the teleconference call will be made available on the Company's Investors site. The full analyst notes on Varian Medical Systems are available to download free of charge at:


Align Technology, Inc. Analyst Notes
On June 23, 2014, Align Technology, Inc. (Align Technology) announced that the Company's application for Binding Corporate Rules (BCRs) for the controller and processor sides of its business has been approved by National Data Protection Authorities in the European Economic Area. BCR offers an advantageous solution over other cross-border transfer mechanisms by harmonizing practices relating to the protection of personal data within a Company, and reduces risks from data transfers to third countries. The European Commission's Data Protection Directive (95/46/EC) only permits the transfer of personal data to non-European Union countries under certain defined standards. At present, only 53 companies, including Align, have been granted approval on BCRs. Roger E. George, Align Technology Vice President and General Counsel, said, "We have high standards for our business practices as reflected in our privacy program and now recognized by the European Data Protection Authorities." The full analyst notes on Align Technology are available to download free of charge at:


About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts Review